{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T12:30:12Z","timestamp":1789475412815,"version":"build-2803163510"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T00:00:00Z","timestamp":1762992000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T00:00:00Z","timestamp":1762992000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Ulm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To evaluate the long-term benefit of early targeted panretinal photocoagulation (PRP) combined with anti-VEGF therapy (IVL group) versus anti-VEGF monotherapy (IV group) in treatment-na\u00efve eyes with macular edema (ME) secondary to ischemic RVO.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective analysis of 143 patients (85 IVL, 58 IV) with ischemic RVO. Baseline ischemic index (IsI), central retinal thickness (CRT), best-corrected visual acuity (BCVA), and age were adjusted.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Over 48 months, the IVL group showed a reduction in mean CRT from 475.6\u2009\u00b1\u2009117.3\u00a0\u03bcm to 282.0\u2009\u00b1\u200969.5\u00a0\u03bcm and improved BCVA from 0.61\u2009\u00b1\u20090.34 LogMAR to 0.44\u2009\u00b1\u20090.34 LogMAR. The IV group demonstrated CRT reduction from 479.4\u2009\u00b1\u2009135.5\u00a0\u03bcm to 340.9\u2009\u00b1\u2009127.3\u00a0\u03bcm and BCVA improvement from 0.58\u2009\u00b1\u20090.32 LogMAR to 0.50\u2009\u00b1\u20090.43 LogMAR. The IVL group received 26.0\u2009\u00b1\u20098.6 intravitreal anti-VEGF treatments (IVT), compared to 25.5\u2009\u00b1\u20096.2 IVT in the IV group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The IVL group exhibited a trend toward better treatment response, particularly in patients with severe retinal ischemia, though findings were not statistically significant. Baseline IsI quantification is recommended for optimal RVO management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12886-025-04496-9","type":"journal-article","created":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T14:28:44Z","timestamp":1763044124000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Potential sustained benefits of early targeted panretinal photocoagulation in combination with anti-VEGF in macular edema secondary to retinal vein occlusion: 48-month results of a retrospective comparative study"],"prefix":"10.1186","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4134-091X","authenticated-orcid":false,"given":"Adnan","family":"Kilani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koray","family":"Bayhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9833-2200","authenticated-orcid":false,"given":"Efstathios","family":"Vounotrypidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1032-6675","authenticated-orcid":false,"given":"Denise","family":"Vogt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8151-3953","authenticated-orcid":false,"given":"Almut","family":"Bindewald-Wittich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3922-3765","authenticated-orcid":false,"given":"Christian","family":"Enders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6991-2214","authenticated-orcid":false,"given":"Armin","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,13]]},"reference":[{"key":"4496_CR1","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1159\/000502041","volume":"242","author":"U Schmidt-Erfurth","year":"2019","unstructured":"Schmidt-Erfurth U, Garcia-Arumi J, Gerendas BS, Midena E, Sivaprasad S, Tadayoni R, Wolf S, Loewenstein A. Guidelines for the management of retinal vein occlusion by the European society of retina specialists (EURETINA). Ophthalmologica. 2019;242:123\u201362. https:\/\/doi.org\/10.1159\/000502041.","journal-title":"Ophthalmologica"},{"key":"4496_CR2","doi-asserted-by":"publisher","unstructured":"Rogers S, McIntosh RL, Cheung N, Lim L, Wang JJ, Mitchell P, Kowalski JW, Nguyen H, Wong TY, International Eye Disease C. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology. 2010;117:313\u2013319 e311 https:\/\/doi.org\/10.1016\/j.ophtha.2009.07.017.","DOI":"10.1016\/j.ophtha.2009.07.017"},{"key":"4496_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-022-02265-2","author":"S Arepalli","year":"2022","unstructured":"Arepalli S, Wykoff CC, Abraham JR, Lunasco L, Yu H, Hu M, Srivastava SK, Reese JL, Brown D, Ehlers JP. Longitudinal analysis of aqueous humour cytokine expression and OCT-based imaging biomarkers in retinal vein occlusions treated with anti-vascular endothelial growth factor therapy in the IMAGINE study. Eye (Lond). 2022. https:\/\/doi.org\/10.1038\/s41433-022-02265-2.","journal-title":"Eye (Lond)"},{"key":"4496_CR4","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1016\/j.ophtha.2012.05.017","volume":"119","author":"R Varma","year":"2012","unstructured":"Varma R, Bressler NM, Suner I, Lee P, Dolan CM, Ward J, Colman S, Rubio RG, Bravo, Groups CS. Improved vision-related function after Ranibizumab for macular edema after retinal vein occlusion: results from the BRAVO and CRUISE trials. Ophthalmology. 2012;119:2108\u201318. https:\/\/doi.org\/10.1016\/j.ophtha.2012.05.017.","journal-title":"Ophthalmology"},{"key":"4496_CR5","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1016\/j.ophtha.2013.11.022","volume":"121","author":"AB Thach","year":"2014","unstructured":"Thach AB, Yau L, Hoang C, Tuomi L. Time to clinically significant visual acuity gains after Ranibizumab treatment for retinal vein occlusion: BRAVO and CRUISE trials. Ophthalmology. 2014;121:1059\u201366. https:\/\/doi.org\/10.1016\/j.ophtha.2013.11.022.","journal-title":"Ophthalmology"},{"key":"4496_CR6","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1016\/j.ophtha.2012.01.042","volume":"119","author":"D Boyer","year":"2012","unstructured":"Boyer D, Heier J, Brown DM, Clark WL, Vitti R, Berliner AJ, Groetzbach G, Zeitz O, Sandbrink R, Zhu X, Beckmann K, Haller JA. Vascular endothelial growth factor Trap-Eye for macular edema secondary to central retinal vein occlusion: six-month results of the phase 3 COPERNICUS study. Ophthalmology. 2012;119:1024\u201332. https:\/\/doi.org\/10.1016\/j.ophtha.2012.01.042.","journal-title":"Ophthalmology"},{"key":"4496_CR7","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1136\/bjophthalmol-2012-301504","volume":"97","author":"FG Holz","year":"2013","unstructured":"Holz FG, Roider J, Ogura Y, Korobelnik JF, Simader C, Groetzbach G, Vitti R, Berliner AJ, Hiemeyer F, Beckmann K, Zeitz O, Sandbrink R. VEGF Trap-Eye for macular oedema secondary to central retinal vein occlusion: 6-month results of the phase III GALILEO study. Br J Ophthalmol. 2013;97:278\u201384. https:\/\/doi.org\/10.1136\/bjophthalmol-2012-301504.","journal-title":"Br J Ophthalmol"},{"key":"4496_CR8","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1001\/jamaophthalmol.2018.4973","volume":"136","author":"IL McAllister","year":"2018","unstructured":"McAllister IL, Smithies LA, Chen FK, Mackey DA, Sanfilippo PG. Two-Year efficacy of Ranibizumab plus Laser-Induced chorioretinal anastomosis vs Ranibizumab monotherapy for central retinal vein occlusion: A randomized clinical trial. JAMA Ophthalmol. 2018;136:1391\u20137. https:\/\/doi.org\/10.1001\/jamaophthalmol.2018.4973.","journal-title":"JAMA Ophthalmol"},{"key":"4496_CR9","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/j.ophtha.2009.09.019","volume":"117","author":"PS Prasad","year":"2010","unstructured":"Prasad PS, Oliver SC, Coffee RE, Hubschman JP, Schwartz SD. Ultra wide-field angiographic characteristics of branch retinal and hemicentral retinal vein occlusion. Ophthalmology. 2010;117:780\u20134. https:\/\/doi.org\/10.1016\/j.ophtha.2009.09.019.","journal-title":"Ophthalmology"},{"key":"4496_CR10","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1097\/IAE.0000000000000148","volume":"34","author":"M Singer","year":"2014","unstructured":"Singer M, Tan CS, Bell D, Sadda SR. Area of peripheral retinal nonperfusion and treatment response in branch and central retinal vein occlusion. Retina. 2014;34:1736\u201342. https:\/\/doi.org\/10.1097\/IAE.0000000000000148.","journal-title":"Retina"},{"key":"4496_CR11","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1097\/IAE.0b013e3181e36c6d","volume":"31","author":"I Tsui","year":"2011","unstructured":"Tsui I, Kaines A, Havunjian MA, Hubschman S, Heilweil G, Prasad PS, Oliver SC, Yu F, Bitrian E, Hubschman JP, Friberg T, Schwartz SD. Ischemic index and neovascularization in central retinal vein occlusion. Retina. 2011;31:105\u201310. https:\/\/doi.org\/10.1097\/IAE.0b013e3181e36c6d.","journal-title":"Retina"},{"key":"4496_CR12","doi-asserted-by":"publisher","first-page":"5946","DOI":"10.1167\/iovs.17-22739","volume":"58","author":"M Gozawa","year":"2017","unstructured":"Gozawa M, Takamura Y, Miyake S, Matsumura T, Morioka M, Yamada Y, Inatani M. Photocoagulation of the retinal nonperfusion area prevents the expression of the vascular endothelial growth factor in an animal model. Invest Ophthalmol Vis Sci. 2017;58:5946\u201353. https:\/\/doi.org\/10.1167\/iovs.17-22739.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"4496_CR13","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.ophtha.2012.09.032","volume":"120","author":"PA Campochiaro","year":"2013","unstructured":"Campochiaro PA, Bhisitkul RB, Shapiro H, Rubio RG. Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion. Ophthalmology. 2013;120:795\u2013802. https:\/\/doi.org\/10.1016\/j.ophtha.2012.09.032.","journal-title":"Ophthalmology"},{"key":"4496_CR14","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1007\/s00417-013-2528-8","volume":"252","author":"M Rehak","year":"2014","unstructured":"Rehak M, Tilgner E, Franke A, Rauscher FG, Brosteanu O, Wiedemann P. Early peripheral laser photocoagulation of nonperfused retina improves vision in patients with central retinal vein occlusion (Results of a proof of concept study). Graefes Arch Clin Exp Ophthalmol. 2014;252:745\u201352. https:\/\/doi.org\/10.1007\/s00417-013-2528-8.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"4496_CR15","doi-asserted-by":"publisher","first-page":"e225","DOI":"10.1111\/aos.12721","volume":"94","author":"Y Tomomatsu","year":"2016","unstructured":"Tomomatsu Y, Tomomatsu T, Takamura Y, Gozawa M, Arimura S, Takihara Y, Inatani M. Comparative study of combined bevacizumab\/targeted photocoagulation vs bevacizumab alone for macular oedema in ischaemic branch retinal vein occlusions. Acta Ophthalmol. 2016;94:e225\u2013230. https:\/\/doi.org\/10.1111\/aos.12721.","journal-title":"Acta Ophthalmol"},{"key":"4496_CR16","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1136\/bjophthalmol-2011-300774","volume":"96","author":"MM Wessel","year":"2012","unstructured":"Wessel MM, Nair N, Aaker GD, Ehrlich JR, D\u2019Amico DJ, Kiss S. Peripheral retinal ischaemia, as evaluated by ultra-widefield fluorescein angiography, is associated with diabetic macular oedema. Br J Ophthalmol. 2012;96:694\u20138. https:\/\/doi.org\/10.1136\/bjophthalmol-2011-300774.","journal-title":"Br J Ophthalmol"},{"key":"4496_CR17","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/j.ophtha.2017.01.049","volume":"124","author":"CC Wykoff","year":"2017","unstructured":"Wykoff CC, Ou WC, Wang R, Brown DM, Cone C, Zamora D, Le RT, Sagong M, Wang K, Sadda SR, Group WS. Peripheral laser for recalcitrant macular edema owing to retinal vein occlusion: the WAVE trial. Ophthalmology. 2017;124:919\u201321. https:\/\/doi.org\/10.1016\/j.ophtha.2017.01.049.","journal-title":"Ophthalmology"},{"key":"4496_CR18","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1016\/j.ophtha.2015.04.006","volume":"122","author":"PA Campochiaro","year":"2015","unstructured":"Campochiaro PA, Hafiz G, Mir TA, Scott AW, Solomon S, Zimmer-Galler I, Sodhi A, Duh E, Ying H, Wenick A, Shah SM, Do DV, Nguyen QD, Kherani S, Sophie R. Scatter photocoagulation does not reduce macular edema or treatment burden in patients with retinal vein occlusion: the RELATE trial. Ophthalmology. 2015;122:1426\u201337. https:\/\/doi.org\/10.1016\/j.ophtha.2015.04.006.","journal-title":"Ophthalmology"},{"key":"4496_CR19","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1016\/j.ophtha.2017.06.027","volume":"124","author":"R Tadayoni","year":"2017","unstructured":"Tadayoni R, Waldstein SM, Boscia F, Gerding H, Gekkieva M, Barnes E, Das Gupta A, Wenzel A, Pearce I, Group BS. Sustained benefits of Ranibizumab with or without laser in branch retinal vein occlusion: 24-Month results of the BRIGHTER study. Ophthalmology. 2017;124:1778\u201387. https:\/\/doi.org\/10.1016\/j.ophtha.2017.06.027.","journal-title":"Ophthalmology"},{"key":"4496_CR20","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.ophtha.2017.11.026","volume":"125","author":"DM Brown","year":"2018","unstructured":"Brown DM, Ou WC, Wong TP, Kim RY, Croft DE, Wykoff CC, Group DS. Targeted retinal photocoagulation for diabetic macular edema with peripheral retinal nonperfusion: Three-Year randomized DAVE trial. Ophthalmology. 2018;125:683\u201390. https:\/\/doi.org\/10.1016\/j.ophtha.2017.11.026.","journal-title":"Ophthalmology"},{"key":"4496_CR21","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1038\/s41433-019-0342-1","volume":"33","author":"SJ Talks","year":"2019","unstructured":"Talks SJ, Bhatia D, Menon G, Cole A, Eleftheriadis H, Downey L, Chong NV, Sivaprasad S, group RDPs. Randomised trial of wide-field guided PRP for diabetic macular oedema treated with Ranibizumab. Eye (Lond). 2019;33:930\u20137. https:\/\/doi.org\/10.1038\/s41433-019-0342-1.","journal-title":"Eye (Lond)"},{"key":"4496_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2025.04.021","author":"DH Lee","year":"2025","unstructured":"Lee DH, Vitale S, Agron E, Keenan TDL, Cukras CA, Chew EY. Visual field changes in diabetic retinopathy: natural history and after Pan-Retinal photocoagulation in the diabetic retinopathy study and the ETDRS. Ophthalmol Retina DOI. 2025. https:\/\/doi.org\/10.1016\/j.oret.2025.04.021.","journal-title":"Ophthalmol Retina DOI"}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-025-04496-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12886-025-04496-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-025-04496-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T14:28:45Z","timestamp":1763044125000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcophthalmol.biomedcentral.com\/articles\/10.1186\/s12886-025-04496-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,13]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4496"],"URL":"https:\/\/doi.org\/10.1186\/s12886-025-04496-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6784838\/v1","asserted-by":"object"}]},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,13]]},"assertion":[{"value":"30 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study, approved by the University of Ulm\u2019s Ethics Committee (Ethikkommission der Universit\u00e4t Ulm, application number 277\/21), adhered to the Declaration of Helsinki. Given its retrospective nature and the use of anonymized data, the ethics committee granted a waiver of informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"643"}}